NCT03146650View on ClinicalTrials.gov

Nivolumab and Ipilimumab in Treating Patients With Metastatic/Recurrent ACC of All Sites and Non-ACC Salivary Gland Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

May 19, 2017

Primary Completion Date

February 24, 2021

Study Completion Date

August 11, 2025

Conditions
Major Salivary Gland CarcinomaMinor Salivary Gland CarcinomaRecurrent Salivary Gland CarcinomaStage IV Major Salivary Gland CarcinomaStage IVA Major Salivary Gland CarcinomaStage IVB Major Salivary Gland CarcinomaStage IVC Major Salivary Gland Carcinoma
Interventions
BIOLOGICAL

Ipilimumab

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

BIOLOGICAL

Nivolumab

Given IV

Trial Locations (1)

60611

Northwestern University, Chicago

Sponsors

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

collaborator

National Cancer Institute (NCI)

NIH

lead

Northwestern University

OTHER